Hypertension, Pulmonary

Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy

A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.

Upfront Combination Pulmonary Arterial Hypertension Therapy

Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)

Rapid Switch From Flolan to Remodulin in the Outpatient Clinic

Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction

Riociguat in Children With Pulmonary Arterial Hypertension (PAH)

Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor

A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study

A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension

BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension

Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension

THERAPY-HYBRID-BPA Trial

Coronary Vasomotor Response After Riociguat Exposure

Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)

An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension

Safety of Terbogrel in Patients With Primary Pulmonary Hypertension

Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension

Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension

This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Interaction With HIV Antiretroviral Agents

Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women

Relative Bioavailability Study

Relative Bioavailability and Food Effect Study

Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight

Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil

Effect of Food on the Pharmacokinetics of Oral Treprostinil

Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TID

Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.

Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG

Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD

A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)

Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension

Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)

Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)

Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)

A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice

Electronic Activity Level Monitoring Pilot in Pulmonary Hypertension

Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)

Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )

EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension

Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation

Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients

Iloprost Therapy in Patients With Critical Limb Ischemia

Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years

Endothelial Function in Patients With Pulmonary Arterial Hypertension

Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension